HUP0300048A3 - Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication and their use - Google Patents
Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication and their useInfo
- Publication number
- HUP0300048A3 HUP0300048A3 HU0300048A HUP0300048A HUP0300048A3 HU P0300048 A3 HUP0300048 A3 HU P0300048A3 HU 0300048 A HU0300048 A HU 0300048A HU P0300048 A HUP0300048 A HU P0300048A HU P0300048 A3 HUP0300048 A3 HU P0300048A3
- Authority
- HU
- Hungary
- Prior art keywords
- disintoxication
- smoker
- nicotine
- transdermal
- dosage forms
- Prior art date
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title 1
- 239000013543 active substance Substances 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 229960002715 nicotine Drugs 0.000 title 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10018834A DE10018834A1 (de) | 2000-04-15 | 2000-04-15 | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
PCT/EP2001/003712 WO2001080837A2 (de) | 2000-04-15 | 2001-04-02 | Transdermale oder transmucosale darreichungsformen mit einer nicotinhaltigen wirkstoffkombination zur raucherentwöhnung |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0300048A2 HUP0300048A2 (hu) | 2003-06-28 |
HUP0300048A3 true HUP0300048A3 (en) | 2005-04-28 |
Family
ID=7638944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0300048A HUP0300048A3 (en) | 2000-04-15 | 2001-04-02 | Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication and their use |
Country Status (22)
Country | Link |
---|---|
US (1) | US20030049308A1 (hu) |
EP (1) | EP1274405B1 (hu) |
JP (1) | JP2004501090A (hu) |
KR (1) | KR100601901B1 (hu) |
CN (1) | CN1423556A (hu) |
AR (1) | AR028327A1 (hu) |
AT (1) | ATE268168T1 (hu) |
AU (1) | AU5624601A (hu) |
BR (1) | BR0110060A (hu) |
CA (1) | CA2404581A1 (hu) |
DE (2) | DE10018834A1 (hu) |
DK (1) | DK1274405T3 (hu) |
ES (1) | ES2220772T3 (hu) |
HK (1) | HK1051495A1 (hu) |
HU (1) | HUP0300048A3 (hu) |
IL (1) | IL152152A0 (hu) |
MX (1) | MXPA02009104A (hu) |
NZ (1) | NZ521155A (hu) |
PL (1) | PL358212A1 (hu) |
RU (1) | RU2301671C2 (hu) |
WO (1) | WO2001080837A2 (hu) |
ZA (1) | ZA200206758B (hu) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10224612A1 (de) * | 2002-06-04 | 2003-12-24 | Lohmann Therapie Syst Lts | Wirkstoffhaltige filmförmige Zubereitungen mit verbesserter chemischer Stabilität, und Verfahren zu deren Herstellung |
EP1551393A4 (en) * | 2002-07-30 | 2010-06-16 | Peter Migaly | COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS |
DE10256775A1 (de) * | 2002-12-05 | 2004-06-24 | Lts Lohmann Therapie-Systeme Ag | Filmförmige Zubereitungen zur transmucosalen Verabreichung von Nicotin, sowie Verfahren zu deren Herstellung |
BR0317771A (pt) | 2002-12-27 | 2005-11-22 | Otsuka Pharma Co Ltd | Composição farmacêutica, uso da mesma, e, método de tratar distúrbios em um paciente |
AR042806A1 (es) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
DE10354894A1 (de) * | 2003-11-24 | 2005-07-07 | Hf Arzneimittelforschung Gmbh | Orale Formulierungen des Desoxypeganins und deren Anwendungen |
DE102004019916A1 (de) * | 2004-04-21 | 2005-11-17 | Grünenthal GmbH | Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster |
WO2005115471A2 (en) * | 2004-05-27 | 2005-12-08 | Neurocure Ltd. | Methods and compositions for treatment of nicotine dependence and dementias |
DE102005007859A1 (de) * | 2005-02-21 | 2006-08-24 | Lts Lohmann Therapie-Systeme Ag | Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen |
DE102005010255A1 (de) | 2005-03-07 | 2006-09-14 | Lts Lohmann Therapie-Systeme Ag | Faserfreies transdermales therapeutisches System und Verfahren zu seiner Herstellung |
EP1993509A2 (en) | 2006-02-17 | 2008-11-26 | Novartis AG | Disintegrable oral films |
DE102006027795A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Raucherentwöhnungs-Kombinationswafer |
DE102006027792A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Antidepressiva-Kombinations-Wafer |
EP2500015A1 (en) * | 2006-12-05 | 2012-09-19 | Landec Corporation | Delivery of drugs |
CA2678876C (en) | 2007-03-07 | 2015-11-24 | Novartis Ag | Orally administrable films |
CL2008003507A1 (es) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
FR2926221A1 (fr) * | 2008-01-14 | 2009-07-17 | Tassin Thomas | Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand. |
CA2896055C (en) * | 2012-12-28 | 2021-02-16 | Noven Pharmaceuticals, Inc. | Compositions and methods for transdermal delivery of amphetamine and clonidine |
WO2014145045A1 (en) * | 2013-03-15 | 2014-09-18 | Tonix Pharmaceuticals, Inc. | Compositions and methods for transmucosal absorption |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
AU2020259406A1 (en) | 2019-04-17 | 2021-11-04 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2265364B1 (hu) * | 1974-03-29 | 1977-11-04 | Creat | |
CH643260A5 (fr) * | 1980-05-02 | 1984-05-30 | Nestle Sa | 1-allyl-3-butyl-8-methylxanthine, procede de preparation et utilisation dans un medicament. |
US4385053A (en) * | 1981-03-11 | 1983-05-24 | Barry Reisberg | Treatment for human memory impairment associated with aging |
US5783207A (en) * | 1985-05-01 | 1998-07-21 | University Of Utah Research Foundation | Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine |
GB8612366D0 (en) * | 1986-05-21 | 1986-06-25 | Erba Farmitalia | Ergoline esters |
US5059600A (en) * | 1989-03-31 | 1991-10-22 | Yale University | Treating habit disorders |
US5219858A (en) * | 1990-03-27 | 1993-06-15 | Parnell Pharmaceuticals, Inc. | Method and compositions for effecting withdrawal from drug dependency |
CA2075517C (en) * | 1992-04-01 | 1997-03-11 | John Wick | Transdermal patch incorporating a polymer film incorporated with an active agent |
DE4301782C1 (de) * | 1993-01-23 | 1994-08-25 | Lohmann Therapie Syst Lts | Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit |
ES2139077T3 (es) * | 1994-06-02 | 2000-02-01 | Dan Riga | Medicamento contra el estres, la degeneracion y el envejecimiento y proceso para su fabricacion. |
AU2703795A (en) * | 1994-06-23 | 1996-01-19 | Procter & Gamble Company, The | Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine |
DE19527925C2 (de) * | 1995-07-29 | 1997-07-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit einer trennmittelbeschichteten Schutzschicht |
JPH11505547A (ja) * | 1996-03-13 | 1999-05-21 | エール ユニバーシティ | ナルトレキソン及び関連化合物を用いる禁煙処置 |
AU6358898A (en) * | 1996-09-09 | 1998-04-17 | Alexander V Kabanov | Fluorinated copolymeric pharmaceutical adjuncts |
AU6250299A (en) * | 1998-09-24 | 2000-04-10 | Algos Pharmaceutical Corporation | Method for reducing nicotine dependency |
US6224897B1 (en) * | 1998-09-29 | 2001-05-01 | Novartis Consumer Health S.A. | Methods to abate the use of tobacco by humans |
US6121289A (en) * | 1998-10-09 | 2000-09-19 | Theramax, Inc. | Method for enhanced brain delivery of nicotinic antagonist |
US6475514B1 (en) * | 1998-12-03 | 2002-11-05 | Andrew Blitzer | Athletic patch |
KR100603168B1 (ko) * | 1998-12-18 | 2006-07-24 | 알자 코포레이션 | 투명한 경피성 니코틴 전달 장치 |
CN1239656A (zh) * | 1999-02-10 | 1999-12-29 | 重庆医科大学 | 戒烟用复方烟碱与可乐定透皮贴剂 |
IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
-
2000
- 2000-04-15 DE DE10018834A patent/DE10018834A1/de not_active Ceased
-
2001
- 2001-04-02 BR BR0110060-2A patent/BR0110060A/pt not_active IP Right Cessation
- 2001-04-02 PL PL01358212A patent/PL358212A1/xx not_active Application Discontinuation
- 2001-04-02 MX MXPA02009104A patent/MXPA02009104A/es unknown
- 2001-04-02 IL IL15215201A patent/IL152152A0/xx unknown
- 2001-04-02 US US10/257,564 patent/US20030049308A1/en not_active Abandoned
- 2001-04-02 AU AU5624601A patent/AU5624601A/xx active Pending
- 2001-04-02 JP JP2001577936A patent/JP2004501090A/ja not_active Withdrawn
- 2001-04-02 DK DK01929488T patent/DK1274405T3/da active
- 2001-04-02 HU HU0300048A patent/HUP0300048A3/hu unknown
- 2001-04-02 CN CN01807994A patent/CN1423556A/zh active Pending
- 2001-04-02 WO PCT/EP2001/003712 patent/WO2001080837A2/de active IP Right Grant
- 2001-04-02 DE DE50102481T patent/DE50102481D1/de not_active Expired - Lifetime
- 2001-04-02 AT AT01929488T patent/ATE268168T1/de not_active IP Right Cessation
- 2001-04-02 ES ES01929488T patent/ES2220772T3/es not_active Expired - Lifetime
- 2001-04-02 CA CA002404581A patent/CA2404581A1/en not_active Abandoned
- 2001-04-02 NZ NZ521155A patent/NZ521155A/en not_active Application Discontinuation
- 2001-04-02 EP EP01929488A patent/EP1274405B1/de not_active Expired - Lifetime
- 2001-04-02 KR KR1020027011637A patent/KR100601901B1/ko not_active IP Right Cessation
- 2001-04-02 RU RU2002123887/15A patent/RU2301671C2/ru not_active IP Right Cessation
- 2001-04-11 AR ARP010101728A patent/AR028327A1/es unknown
-
2002
- 2002-08-23 ZA ZA200206758A patent/ZA200206758B/en unknown
-
2003
- 2003-05-23 HK HK03103650A patent/HK1051495A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PL358212A1 (en) | 2004-08-09 |
RU2002123887A (ru) | 2004-03-10 |
AU5624601A (en) | 2001-11-07 |
JP2004501090A (ja) | 2004-01-15 |
ZA200206758B (en) | 2003-10-01 |
IL152152A0 (en) | 2003-05-29 |
EP1274405B1 (de) | 2004-06-02 |
AR028327A1 (es) | 2003-05-07 |
EP1274405A2 (de) | 2003-01-15 |
CN1423556A (zh) | 2003-06-11 |
KR20030025909A (ko) | 2003-03-29 |
DE50102481D1 (de) | 2004-07-08 |
AU2001256246B2 (en) | 2005-03-03 |
CA2404581A1 (en) | 2002-09-26 |
KR100601901B1 (ko) | 2006-07-14 |
ATE268168T1 (de) | 2004-06-15 |
ES2220772T3 (es) | 2004-12-16 |
RU2301671C2 (ru) | 2007-06-27 |
NZ521155A (en) | 2006-02-24 |
DK1274405T3 (da) | 2004-10-11 |
WO2001080837A2 (de) | 2001-11-01 |
DE10018834A1 (de) | 2001-10-25 |
BR0110060A (pt) | 2003-07-15 |
HK1051495A1 (en) | 2003-08-08 |
WO2001080837A3 (de) | 2002-02-21 |
HUP0300048A2 (hu) | 2003-06-28 |
MXPA02009104A (es) | 2003-03-12 |
US20030049308A1 (en) | 2003-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0300048A3 (en) | Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication and their use | |
AU8206401A (en) | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels | |
IL154012A0 (en) | Hydrogel-driven drug dosage form | |
AU6501201A (en) | Systems and methods for monitoring health and delivering drugs transdermally | |
IL149224A0 (en) | Hydrogen-driven drug dosage form | |
EG24408A (en) | Low dose entecavir formulation and use | |
AU7490700A (en) | Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing | |
HK1034453A1 (en) | Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine | |
DE60201134D1 (de) | Nicotinhaltige transdermale Darreichungsform zur Raucherentwöhnung | |
EE200200498A (et) | Asendatud 3-fenüül-5-alkoksü-1,3,4-oksadiasol-2-oon, selle valmistamine ja kasutamine hormoontundlikku lipaasi pärssivas ravimis ning seda sisaldav suhkurtõve ravim | |
EP1280485A4 (en) | TRANSDERMAL STAMP FOR IMPROVED MEDICINE | |
HUP0200189A3 (en) | Transdermal therapeutic system with nicotine | |
PL360885A1 (en) | 10-aryl-11h-benzo [b]fluorene derivatives and analogs for medicinal use | |
HUP0104728A3 (en) | Transparent transdermal nicotine delivery device | |
IL137559A0 (en) | Transdermal drug delivery system | |
HK1040196A1 (zh) | 低劑量艾替開韋製劑及其應用 | |
AU2003289929A1 (en) | Transmucosal and transdermal medicaments with an improved active ingredient absorption | |
AU2001256246B9 (en) | Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication | |
AU2001256246A1 (en) | Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication | |
HUP0105097A3 (en) | Pharmaceutical mixtures comprising a combination of a profen and other active compounds | |
AU6269901A (en) | Biologically active agents and drugs | |
AU7053701A (en) | Dosage of transdermal delivery systems | |
NZ522948A (en) | Active substance combination containing a compound with an opioid effect and at least one further compound of the thyrotropin releasing hormone analog of formula I in the treatment of pain | |
IL149115A0 (en) | Transdermal drug delivery devices | |
HU0500745D0 (en) | Rapidly decomposable pharmaceutical dosage form for use in oral or body cavity containing nicotine as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |